FULC vs. OCUL, ANIP, VERA, TWST, DYN, APGE, COGT, TLRY, ABCL, and IMCR
Should you be buying Fulcrum Therapeutics stock or one of its competitors? The main competitors of Fulcrum Therapeutics include Ocular Therapeutix (OCUL), ANI Pharmaceuticals (ANIP), Vera Therapeutics (VERA), Twist Bioscience (TWST), Dyne Therapeutics (DYN), Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Tilray Brands (TLRY), AbCellera Biologics (ABCL), and Immunocore (IMCR). These companies are all part of the "pharmaceutical products" industry.
Fulcrum Therapeutics vs. Its Competitors
Ocular Therapeutix (NASDAQ:OCUL) and Fulcrum Therapeutics (NASDAQ:FULC) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.
Ocular Therapeutix presently has a consensus target price of $22.63, suggesting a potential upside of 90.93%. Fulcrum Therapeutics has a consensus target price of $9.60, suggesting a potential upside of 9.71%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, research analysts clearly believe Ocular Therapeutix is more favorable than Fulcrum Therapeutics.
Fulcrum Therapeutics has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -382.51%. Fulcrum Therapeutics' return on equity of -31.05% beat Ocular Therapeutix's return on equity.
59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 2.3% of Ocular Therapeutix shares are held by insiders. Comparatively, 7.0% of Fulcrum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Fulcrum Therapeutics has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.
Ocular Therapeutix has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.93, indicating that its share price is 193% more volatile than the S&P 500.
In the previous week, Ocular Therapeutix had 9 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 21 mentions for Ocular Therapeutix and 12 mentions for Fulcrum Therapeutics. Ocular Therapeutix's average media sentiment score of 0.59 beat Fulcrum Therapeutics' score of 0.50 indicating that Ocular Therapeutix is being referred to more favorably in the media.
Summary
Fulcrum Therapeutics beats Ocular Therapeutix on 11 of the 17 factors compared between the two stocks.
Get Fulcrum Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FULC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fulcrum Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:FULC) was last updated on 10/14/2025 by MarketBeat.com Staff
